ARTICLES BY JEFFREY S. BUGULISKIS, PHD
-
Six Specialized Modalities Testing CDMO Readiness In 20262/27/2026
As biopharma pipelines shift toward more complex therapies, sponsors are finding that CDMO readiness now depends less on general capacity and more on highly specific technical capabilities.
-
The 9 Fastest-Growing Outsourcing Segments10/21/2025
Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.
-
Cell & Gene Therapy Outsourcing's New Paradigm10/7/2025
The industry has flipped from scarcity to surplus, and sponsors now have leverage to set terms, not take numbers.